BACKGROUND: Albuminuria predicts cardiovascular risk, but its function as a marker of endothelial damage and atherosclerosis is uncertain, as is the complex relationship with hypertension and diabetes. OBJECTIVE: To determine whether hypertension contributes to albuminuria across levels of atherosclerosis and type 2 diabetes. METHODS: Cross-sectional associations of cardiovascular risk factors and albuminuria were examined in 10,113 middle-aged participants in the atherosclerosis risk in communities study divided into four subgroups: type 2 diabetes with marked atherosclerosis, type 2 diabetes without marked atherosclerosis, without diabetes with marked atherosclerosis, and without diabetes without marked atherosclerosis. Marked atherosclerosis was defined as high levels of carotid atherosclerosis or prevalent coronary heart disease. RESULTS: Hyperglycemia and hypertriglyceridemia were associated with albuminuria, but only among patients with type 2 diabetes. In multivariate models, increasing blood pressure levels (but not albuminuria) were significantly associated (P-trend <0.001) with carotid atherosclerosis when stratified by prevalent coronary heart disease. Excluding individuals on hypertension medication, higher blood pressure was associated with albuminuria in all groups (P-trend<0.05). The association was strong even for high-normal blood pressure among individuals without diabetes without marked atherosclerosis (odds ratio 2.7, 95% confidence interval 1.6-4.6) and patients with type 2 diabetes with marked atherosclerosis (12.0, 1.3-108.2). CONCLUSION: Blood pressure, even at high-normal levels, is consistently associated with albuminuria across categories of type 2 diabetes and atherosclerosis. Our results suggest that the effects of blood pressure on albuminuria are not solely mediated through generalized vascular damage, as represented by degree of atherosclerosis.
BACKGROUND:Albuminuria predicts cardiovascular risk, but its function as a marker of endothelial damage and atherosclerosis is uncertain, as is the complex relationship with hypertension and diabetes. OBJECTIVE: To determine whether hypertension contributes to albuminuria across levels of atherosclerosis and type 2 diabetes. METHODS: Cross-sectional associations of cardiovascular risk factors and albuminuria were examined in 10,113 middle-aged participants in the atherosclerosis risk in communities study divided into four subgroups: type 2 diabetes with marked atherosclerosis, type 2 diabetes without marked atherosclerosis, without diabetes with marked atherosclerosis, and without diabetes without marked atherosclerosis. Marked atherosclerosis was defined as high levels of carotid atherosclerosis or prevalent coronary heart disease. RESULTS:Hyperglycemia and hypertriglyceridemia were associated with albuminuria, but only among patients with type 2 diabetes. In multivariate models, increasing blood pressure levels (but not albuminuria) were significantly associated (P-trend <0.001) with carotid atherosclerosis when stratified by prevalent coronary heart disease. Excluding individuals on hypertension medication, higher blood pressure was associated with albuminuria in all groups (P-trend<0.05). The association was strong even for high-normal blood pressure among individuals without diabetes without marked atherosclerosis (odds ratio 2.7, 95% confidence interval 1.6-4.6) and patients with type 2 diabetes with marked atherosclerosis (12.0, 1.3-108.2). CONCLUSION: Blood pressure, even at high-normal levels, is consistently associated with albuminuria across categories of type 2 diabetes and atherosclerosis. Our results suggest that the effects of blood pressure on albuminuria are not solely mediated through generalized vascular damage, as represented by degree of atherosclerosis.
Authors: Garabed Eknoyan; Thomas Hostetter; George L Bakris; Lee Hebert; Andrew S Levey; Hans-Henrik Parving; Michael W Steffes; Robert Toto Journal: Am J Kidney Dis Date: 2003-10 Impact factor: 8.860
Authors: R Pedrinelli; G Dell'Omo; G Penno; S Bandinelli; D Giannini; A Balbarini; M Mariani Journal: J Hum Hypertens Date: 2000-12 Impact factor: 3.012
Authors: M A Martínez; A Moreno; A Aguirre de Cárcer; R Cabrera; R Rocha; A Torre; A Nevado; T Ramos; J Neri; G Antón; I Miranda; P Fernández; E Rodríguez; A Miquel; J L Martínez; M Rodríguez; C Eisman; J G Puig Journal: J Hypertens Date: 2001-02 Impact factor: 4.844
Authors: Oemer-Necmi Goek; Anna Köttgen; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh; Brad C Astor Journal: Nephrol Dial Transplant Date: 2012-01-28 Impact factor: 5.992
Authors: Lisa A Cooper; L Ebony Boulware; Edgar R Miller; Sherita Hill Golden; Kathryn A Carson; Gary Noronha; Mary Margaret Huizinga; Debra L Roter; Hsin-Chieh Yeh; Lee R Bone; David M Levine; Felicia Hill-Briggs; Jeanne Charleston; Miyong Kim; Nae-Yuh Wang; Hanan Aboumatar; Jennifer P Halbert; Patti L Ephraim; Frederick L Brancati Journal: Am J Public Health Date: 2013-09-12 Impact factor: 9.308
Authors: Morgan E Grams; Brad C Astor; Lori D Bash; Kunihiro Matsushita; Yaping Wang; Josef Coresh Journal: J Am Soc Nephrol Date: 2010-07-29 Impact factor: 10.121
Authors: Conall M O'Seaghdha; Asya Lyass; Joseph M Massaro; James B Meigs; Josef Coresh; Ralph B D'Agostino; Brad C Astor; Caroline S Fox Journal: Am J Med Date: 2012-03 Impact factor: 4.965
Authors: Conall M O'Seaghdha; Shih-Jen Hwang; Nrupen A Bhavsar; Anna Köttgen; Josef Coresh; Brad C Astor; Caroline S Fox Journal: Am J Kidney Dis Date: 2011-02-03 Impact factor: 8.860
Authors: Saul Blecker; Kunihiro Matsushita; Anna Köttgen; Laura R Loehr; Alain G Bertoni; L Ebony Boulware; Josef Coresh Journal: Am J Kidney Dis Date: 2011-05-06 Impact factor: 8.860
Authors: Deidra C Crews; Laura C Plantinga; Edgar R Miller; Rajiv Saran; Elizabeth Hedgeman; Sharon H Saydah; Desmond E Williams; Neil R Powe Journal: Hypertension Date: 2010-03-22 Impact factor: 10.190
Authors: Conall M O'Seaghdha; Shih-Jen Hwang; Jennifer E Ho; Ramachandran S Vasan; Daniel Levy; Caroline S Fox Journal: J Am Soc Nephrol Date: 2013-06-13 Impact factor: 10.121